Study title:
A phase II gene therapy study in patients with non-small cell lung cancer using SCH58500 (rAd/p53) in combination with chemotherapy for multiple cycles
Date receipt dossier:
18 aug 1997
Pharmaceutical study code:
I97-076-03
Company / Sponsor:
Schering Plough NV/SA
Phase:
II
Treated organism:
Humans
Indication category:
Cancer therapy
Disease:
Non-Small Cell Lung Cancer
Therapeutic approach:
Tumor suppressor gene
Genetic modification:
Wild-type p53
Method of transfer of nucleic acid of interest:
Human Adenovirus serotype 5
Administered biological material:
Recombinant Adenovirus D (E3, E1A, E1B, pIX)
Route of administration:
Intratumoral
Locations in Belgium:
Akademisch Ziekenhuis, Vrije Universiteit Brussel
Type of procedure:
Contained use only
Current status:
Authorized